Aflibercept may reduce risk of PDR and DME in patients with severe NPDR

• Posted on: Jun 4 2021
• By: Saratoga Opthalmology
• Leave a response

Investigators evaluated the efficacy of intravitreous aflibercept injections in mitigating complications in eyes with moderate to severe nonproliferative diabetic retinopathy (NPDR).
Source: AAO

Posted in: Uncategorized